|Day Low/High||2.49 / 2.68|
|52 Wk Low/High||2.54 / 9.95|
Several stocks trading near $5 were poised to move on above-average volume during Wednesday's session.
The J.P. Morgan Healthcare Conference kicks off with a flurry of biotech company updates.
Biotech columnist Adam Feuerstein rolls out the year's first Mailbag, answering questions about Novelos and other stocks.
Several stocks trading near $5 were poised to move on above-average volume during Monday's session.
The pharma giant will develop the drug for inflammatory bowel disease.
Biotech stock watchdog Adam Feuerstein looks back at the best and worst of Mailbag 2009.
BioCryst's fall brings profit taking, while a frustrated bull starts issuing his own press releases.
CEO spotted in New York with bankers in tow, looking at his wallet.
News and highlights from the American Society of Hematology annual meeting.
Carter's stock purchase hardly instills confidence in Hemispherx's future.
New study concludes H1N1 activity may not be any worse than seasonal flu.
Cramer says it's the best-run and best-capitalized company.
Cramer says the stock of the Internet retail giant could top $216 next year.
Will Cel-Sci's flu drug last longer than its other fly-by-night projects?
Hedge funds, Wall Street, SEC and FDA out to hurt maker of flu drug, newsletter writer claims.
Peaking flu season could mean no need for further peramivir orders.
A number of technical developments in the greenback warrant some scrutiny.
U.S. government orders IV versions of two flu drugs to treat hospitalized patients.
Cel-Sci's complaint avoids the central issue about its mystery South African partner.
Initial order lower than expected but priced higher
Cholesterol-lowering statin drugs like Lipitor, Zocor, may improve flu survival, study finds
BioCryst takes bigger 3Q loss after starting late-stage tests of IV flu treatment peramivir
Details emerge on emergency use of peramivir for H1N1 patients.
KBR, RadioShack, WebMD Health, Sohu.com are among big market movers Monday
Premarket roundup: BioCryst jumps on FDA approval, analyst: gains from Netflix-Sony deal murky
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.